Anti-Viral Therapeutics Market Size (2024 - 2029)

The anti-viral therapeutics market is projected to experience growth over the forecast period, driven by factors such as the increased focus on developing treatments for COVID-19 and the rising global patient population requiring therapies for diseases like HIV. The market's expansion is further supported by the launch of new products and intense research and development efforts by major players. However, the high cost of anti-viral drug treatments may pose a challenge to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Antivirals Research Anti-Viral Therapeutics Market Market Size

Market Size of Anti-Viral Therapeutics Industry

Anti Viral Therapeutics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 55.57 Billion
Market Size (2029) USD 61.54 Billion
CAGR (2024 - 2029) 2.06 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Anti-Viral Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Anti-Viral Therapeutics Market Analysis

The Anti-Viral Therapeutics Market size is estimated at USD 55.57 billion in 2024, and is expected to reach USD 61.54 billion by 2029, growing at a CAGR of 2.06% during the forecast period (2024-2029).

The sudden outbreak of COVID-19 had an optimistic effect on the global anti-viral therapeutics market's growth. The strong market growth due to the COVID-19 pandemic was mainly attributed to the increasing focus of major market players on developing COVID-19 drugs. For instance, in January 2022, Pharma major Lupin launched the antiviral drug Molnupiravir in India under the brand name Molnulup for treating COVID-19 adults in the country. Furthermore, Emcure Pharmaceuticals received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India (DCGI) for launching Molnupiravir to treat mild COVID-19. The company plans to launch the oral drug under the brand Lizuvira in the Indian market. Thus, the market responded to the effect quickly and changed in a way that accelerated market growth.

Similarly, product launches are another factor boosting the growth of the market. For instance, in November 2021, Pfizer Inc. announced its investigational COVID-19 oral antiviral candidate, PAXLOVID, and claimed to significantly reduce hospitalization and mortality rate based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The anti-viral therapeutics market is expected to witness an upsurge mainly due to the increasing patient population in the world. According to WHO, globally, 38.4 million people were living with HIV at the end of 2021. An estimated 0.7% of adults aged 15-49 years worldwide live with HIV; however, the epidemic's burden continues to vary considerably between countries and regions. Thus, with an increase in HIV cases, the need for its therapy increased, leading to market growth.

Moreover, intense research & development pipelines of the major players and increasing product launches are the key drivers in the growth of the antiviral therapeutics market. For instance, in April 2021, Atriva Therapeutics GmbH received USD 12.05 million (EUR 11.4 million) in federal funding. The company will use the funds to advance its drug ATR-002, which is currently in a Phase II clinical study called RESPIRE. Anti-viral therapeutics are commercially available for diseases like influenza, hepatitis C, chickenpox, papilloma, and AIDS.

Thus, the abovementioned factors are impacting the market growth for the anti-viral therapeutics market. However, the high cost of anti-viral drug treatment is expected to restrain the market growth.

Anti-Viral Therapeutics Industry Segmentation

Anti-viral drugs are a class of medication used for treating viral infections. While a broad-spectrum antiviral is effective against many viruses, most antivirals target specific viruses. 

Anti-viral Therapeutics Market is Segmented by Drug Type (Herpes Anti-viral Drugs, Hepatitis Anti-viral Drugs, HIV Anti-viral Drugs, Influenza Anti-viral Drugs, and Other Anti-viral Drugs), Distribution Channel (Hospital Pharmacy, Independent Pharmacy, and Drug Store, Online Pharmacy), and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers value (in USD billion) for the above segments.

By Drug Type
Herpes Anti-viral Drugs
Hepatitis Anti-viral Drugs
HIV Anti-viral Drugs
Influenza Anti-viral Drugs
Other Drug Types
By Distribution Channel
Hospital Pharmacy
Independent Pharmacy and Drug Store
Online Pharmacy
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Anti-Viral Therapeutics Market Size Summary

The anti-viral therapeutics market is poised for steady growth over the forecast period, driven by a combination of factors including the aftermath of the COVID-19 pandemic, increasing global patient populations, and robust research and development activities. The pandemic catalyzed significant advancements in the market, with major pharmaceutical companies focusing on developing and launching antiviral drugs to combat COVID-19. This surge in activity not only accelerated market growth but also led to the introduction of new products, such as Molnupiravir and PAXLOVID, which have contributed to the market's expansion. The rising prevalence of viral infections, including HIV, influenza, and hepatitis, has further fueled demand for antiviral therapies, prompting companies to invest heavily in research and development to address unmet medical needs.

North America is expected to maintain its dominance in the anti-viral therapeutics market, supported by a strong presence of established market players and significant investments in research and development. The region's growth is also bolstered by favorable regulatory approvals from the US Food and Drug Administration, which have facilitated the introduction of new antiviral products. The competitive landscape of the market is characterized by the presence of major players such as AbbVie Inc., GlaxoSmithKline PLC, and Merck and Co. Inc., who are employing both organic and inorganic strategies to enhance their market positions. Despite the promising growth prospects, the high cost of antiviral treatments poses a challenge to market expansion, necessitating ongoing innovation and strategic planning by industry participants.

Explore More

Anti-Viral Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies

      2. 1.2.2 Increasing Research & Development Investment

      3. 1.2.3 Growing Burden of HIV Infection

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Anti-viral Drug Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 2.1 By Drug Type

      1. 2.1.1 Herpes Anti-viral Drugs

      2. 2.1.2 Hepatitis Anti-viral Drugs

      3. 2.1.3 HIV Anti-viral Drugs

      4. 2.1.4 Influenza Anti-viral Drugs

      5. 2.1.5 Other Drug Types

    2. 2.2 By Distribution Channel

      1. 2.2.1 Hospital Pharmacy

      2. 2.2.2 Independent Pharmacy and Drug Store

      3. 2.2.3 Online Pharmacy

    3. 2.3 By Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Anti-Viral Therapeutics Market Size FAQs

The Anti-Viral Therapeutics Market size is expected to reach USD 55.57 billion in 2024 and grow at a CAGR of 2.06% to reach USD 61.54 billion by 2029.

In 2024, the Anti-Viral Therapeutics Market size is expected to reach USD 55.57 billion.

Anti-Viral Therapeutics Market Report Snapshots

Anti-Viral Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)